January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.
This study introduced Cadd4, a peptide-based degrader developed using computer-aided drug design, which effectively reduced PCSK9 levels and increased LDL receptor expression, resulting in decreased plasma cholesterol and LDL-C levels in hypercholesterolemic mice, without liver toxicity.
6 citations
,
January 2024 in “ACS Medicinal Chemistry Letters” This study found that the alkaloids cepharanthine and berbamine bind to SK2 and SK3 channel subtypes with affinities that match their concentrations active against various diseases, prompting further investigation into SK channels' role in their therapeutic effects.
January 2014 in “HAL (Le Centre pour la Communication Scientifique Directe)” This review provides an update on sex hormone-associated dermatoses in dogs, detailing known conditions like feminization syndrome and exploring less understood issues such as alopecia X, without presenting new clinical findings.